## **Liverpool** John Moores University

Title: SCIENTIFIC BASIS OF THERAPEUTICS 3

Status: Definitive

Code: **6003SBPHAR** (113418)

Version Start Date: 01-08-2020

Owning School/Faculty: Pharmacy & Biomolecular Sciences Teaching School/Faculty: Pharmacy & Biomolecular Sciences

Team	Leader
Peter Penson	Υ
Neil Henney	
Steve Enoch	
Mark Wainwright	
John Sexton	
James Downing	
Gaynor Bresnen	
Janice Harland	

Academic Credit Total

Level: FHEQ6 Value: 36 Delivered 109

Hours:

Total Private

Learning 360 Study: 251

**Hours:** 

### **Delivery Options**

Course typically offered: Standard Year Long

Component	Contact Hours
Lecture	81
Practical	3
Seminar	3
Tutorial	2
Workshop	17

**Grading Basis:** 40 %

### **Assessment Details**

Category	Short Description	Description	Weighting (%)	Exam Duration
Exam	EXAM	Examination. See module handbok for deti See module handbook for	60	3

Category	Short	Description	Weighting	Exam	
	Description		(%)	Duration	
		details of examination structure			
Portfolio	SDL	Assessed by external tutors, seminar presentation and portfolio. Attendance at all four timetabled sessions is compulsory. See moule handbook for further details.	20		
Report	Blog	Students are required to keep a blog based on primary research relevant to topics studied in the module. Please see the module handbook for further details.	20		

#### **Aims**

- 1. To generate a thorough knowledge of the functional anatomy, pathophysiology, pharmacology and therapeutics of the human cardiovascular system. To present the modes of action, clinical uses, contra-indications, side-effects and interactions of the more commonly used cardiovascular drugs.
- 2.To present the cellular mechanisms underlying the functioning of the CNS and the various drugs which act on it. To explain the organisation of the CNS in relation to function and disorder. To demonstrate the mode of action and clinical use of drugs used to treat CNS disorders. Mental illness and its various causes. Drug development and design of CNS active drugs.
- 3.To introduce fundamental concepts of the defence of the body, and to consider a number of immunological and inflammatory disease states and their treatment.

### **Learning Outcomes**

After completing the module the student should be able to:

- Demonstrate an understanding of the aetiology, pathophysiology and therapeutics of the major cardiovascular diseases.
- 2 Demonstrate the manner in which the basic principles (outlined above) underpin a rational approach to the treatment of those diseases.
- Demonstrate a knowledge of the structures, licensed indications, dosage regimes (including clinical guidelines), side-effects and contra-indications of the major classes of cardiovascular drugs.
- Demonstratean understanding of the physiology relevant to specific aspects of cardiovascular physiology and pharmacology (e.g. recording and analysis of ECG).
- 5 Describe the key areas of the CNS and their functional interrelationships.
- Describe the key stages in CNS development in relation to function and how these stages may be impaired by teratogens.
- 7 Describe the key features of CNS neurone function and the major neurotransmitter systems along with their receptors.
- 8 Relate sensory and motor function to key human activities and relate dysfunction to CNS disorders.
- 9 Demonstrate a knowledge of the causes of mental illness and neurological

- disorders and the drugs used to treat them, including relevant clinical guidelines.
- Describe the major components of body defence systems and explain the interrelationship and functions of these components.
- 11 Identify commonly encountered inflammatory and immunological diseases.
- Advise on the use of drug treatment and immunological manipulations in a wide range of disease states.

### **Learning Outcomes of Assessments**

The assessment item list is assessed via the learning outcomes listed:

EXAM	1	2	3	4	5	6	7	8	9	10	11	12
Student Directed Learning	1	2	3	4	5	6	7	8	9	10	11	12
Blog	1	2	6	7	8	9	11	12				

### **Outline Syllabus**

Physiology of the electrical and mechanical events in the heart cycle. Control of heart rate, myocardial contractility, venous return, cardiac output, blood pressure and blood volume. Formation of lymph and oedema.

Pathophysiology and therapeutics of hypertension, hyperlipidaemia, angina pectoris, myocardial infarction, cardiac dysrhythmia and cardiac failure. The pharmacology of all classes of drugs, with reference to named examples, used in the treatment of the aforementioned diseases.

Development of the CNS and congenital defects. Functional CNS anatomy and histology. Neurochemistry. Major neurotransmission systems and their receptors. Receptor neurobiology and transduction.

Basic neurophysiology, sensory transduction, sensory processing and perception. Brain stem and control of vegetative function. Motor systems. Cortical function and disorders. Neurological disorders and their treatment. Nociception. Pain and analgesia.

Mental illness and its various causes. Major groups of drugs used to treat mental illness and neurological conditions: their mechanisms of action and clinical pharmacology.

Development of CNS drugs, their metabolism and pharmacokinetics.

Drug and substance abuse.

Overview of immunity:innate and adaptive; self; antigens; immune surveillance.

Components: humoral - antibodies, lymphokines, other cytokines; cellular -

lymphocytes, phagocytes, antigen-presenting cells.

Clonal development.

Memory.

Antibody synthesis

Immunisation: Active, passive.

Complement.

Hypersensitivity: Types, treatment.

Inflammation: Vascular changes, cellular responses, mediator concept.

Inflammatory diseases: Arthritis, colitis, dermatitis. Anti-inflammatory drugs: Clinical uses, mechanisms.

HLA

Tissue transplantation: Graft rejection, immune suppression.
Tolerance
Autoimmunity.
Tumour immunology
Immune deficiency: types, diseases.

# **Learning Activities**

Lectures, tutorials, seminars, student-directed learning (problem-based learning), workshops & practicals.

### **Notes**

This Module integrates with Pharmacy Practice at Level 3 and together they underpin therapeutics at Level 4.